Intuitive Surgical Exceeds Q1 Expectations with 23% Revenue Growth and Strong Procedure Volumes
Summary
Intuitive Surgical announced Q1 2026 financial results that significantly beat expectations, reporting 23% revenue growth, strong procedure volume increases, and a $1.1 billion share repurchase.
Key Events
-
Q1 Revenue Exceeds Expectations
First quarter 2026 revenue increased 23% to $2.77 billion, significantly surpassing analyst estimates and the $2.25 billion reported in Q1 2025.
-
Strong Procedure Volume Growth
Worldwide procedures (da Vinci and Ion combined) grew approximately 17% year-over-year, with da Vinci procedures up 16% and Ion procedures up 39%.
-
Increased System Placements
The company placed 431 da Vinci surgical systems (up from 367 in Q1 2025) and 52 Ion endoluminal systems (up from 49 in Q1 2025), expanding its installed base.
-
Significant Share Repurchase
Intuitive Surgical repurchased 2.3 million shares of its common stock for $1.1 billion during the first quarter of 2026.
Analysis
Intuitive Surgical reported first-quarter 2026 results that significantly exceeded analyst expectations, driven by robust growth in procedure volumes and system placements. The company's da Vinci and Ion platforms saw substantial adoption, indicating strong underlying business momentum. This positive performance, coupled with a significant share repurchase program, provides a strong bullish signal, especially as the stock is trading near its 52-week low. The reaffirmed positive outlook for 2026 procedure growth and gross profit margin further reinforces confidence in the company's trajectory.
At the time of this filing, ISRG was trading at $440.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $160.3B. The 52-week trading range was $427.84 to $603.88. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.